Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.

bioRxiv : the preprint server for biology·2026

Same author

Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti-PD-1 Antibody.

Cancer research communications·2026

Same author

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.

Nature communications·2026

Same author

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

Nature communications·2026

Same author

Swallowing Function and Perioperative Complications After Transoral Robotic Surgery.

JAMA otolaryngology-- head & neck surgery·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Mixing it up: boosting responses with immunotherapy combinations.

Hiroki Komatsuda¹, Edward S Sim², Ravindra Uppaluri²

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Trends in Cancer

|May 7, 2025

Summary

Combination neoadjuvant immunotherapy, including anti-PD-1 plus CTLA-4 or LAG-3, shows improved head and neck cancer responses compared to anti-PD-1 alone. Different mechanisms and biomarkers suggest personalized treatment potential.

Keywords:

head and neck cancer immune checkpoint inhibitor neoadjuvant immunotherapy single-cell RNA sequencing

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

Related Experiment Videos

Last Updated: Jun 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors

Published on: August 16, 2024

Area of Science:

Oncology
Immunotherapy
Head and Neck Cancer Research

Background:

Neoadjuvant immunotherapy is being explored for head and neck cancers.
The efficacy of combination immunotherapy regimens requires further investigation.

Purpose of the Study:

To evaluate the effectiveness of combination neoadjuvant immunotherapy strategies in head and neck cancer patients.
To compare responses between different combination regimens and monotherapy.

Main Methods:

Utilized neoadjuvant anti-PD-1 plus CTLA-4 or anti-PD-1 plus LAG-3.
Compared outcomes against anti-PD-1 monotherapy.

Main Results:

Combination strategies (anti-PD-1+CTLA-4 or anti-PD-1+LAG-3) demonstrated enhanced responses.
Observed distinct mechanisms and biomarkers of response for each combination.

Conclusions:

Combination neoadjuvant immunotherapy can improve responses in head and neck cancer.
Personalized treatment approaches are feasible based on distinct biomarkers and mechanisms.